Search Results 421-430 of 35413 for prostate cancer
Share · Tweet . VID-20109921. Home; Mayo Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer: Radiology. There's still time!
Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who ...
Benign prostatic hyperplasia, also called an enlarged prostate, is incredibly common, especially among men over 40. While it's not the same as prostate cancer, ...
About this study. The purpose of this study is to investigate positive surgical margins (PSMs) in subjects undergoing RALP with (e)PLND after intravenous ...
People from around the world seek prostate cancer care at Mayo due to its combination of cutting-edge science, compassionate care and strong outcomes. Mayo ...
... prostate cancer. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
About this study. This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and ...
About this study. The purpose of this study is to collect blood and urine samples from men already diagnosed with advanced prostate cancer.
Prostate cancer: Does PSA level affect prognosis? Prostate-specific antigen (PSA) is a protein made by prostate tissue. Men with prostate cancer often have ...
The purpose of this study is to determine whether an empty bladder during radiation therapy delivery for prostate cancer affects patient-reported urinary ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!